BioMarin SoccerNurds / Apr 30, 2021
Want to see the real deal?
More inside scoop? View in App
More inside scoop? View in App
FOLLOWING
Show more
BioMarin News
BioMarin Entrepreneur / Apr 29, 2021
BMRN stock is consolidating on light volume prior to earnings. The company is projected to report earnings and revenue that are lower on a year-over-year basis. With a potential upside of over 46%, that could make BioMarin an attractive buying option.
Entrepreneur
BioMarin PRNewswire / Apr 29, 2021
PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2021 2020 % Change Total...
PRNewswire
BioMarin The Edwardsville Intelligencer / Apr 29, 2021
SAN RAFAEL, Calif. (AP) _ BioMarin Pharmaceutical Inc. (BMRN) on Thursday reported first-quarter net income of $17.4 million. On a per-share basis, the San Rafael, California-based company said it had profit of 9 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 56 cents per share.
BioMarin: Q1 Earnings Snapshot
The Edwardsville Intelligencer
BioMarin Nasdaq / Apr 29, 2021
(RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) revealed earnings for first quarter that declined from the same period last year.The company's earnings came in at $17.37 million, or $0.09 per share. This compares with $81.38 million, or $0.44 per share, in last year's first quar
BioMarin Benzinga / Apr 29, 2021
Shares of Biomarin Pharmaceutical (NASDAQ: BMRN) decreased in after-market trading after the company reported Q1 results. Earnings per share decreased 79.55% over the past year to $0.09, which beat the estimate of ($0.10). Revenue of $486,030,000 decreased by 3.19% year over year, which beat the estimate of $446,450,000.
Benzinga
BioMarin Nasdaq / Apr 29, 2021
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.63 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 75%.
BioMarin Yahoo Finance / Apr 29, 2021
The stock of Biomarin Pharmaceutical ( NAS:BMRN, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance.
BioMarin Seeking Alpha / Apr 29, 2021
The FDA has extended the PDUFA data for BioMarin's short stature treatment vosoritide by three months to November 20, 2021, to review two-year phase 3 data.
BioMarin Investing.com / Apr 29, 2021
Ground control out, remote control in at London City Airport By Sarah Young LONDON (Reuters) - At London City Airport, the air traffic controllers have gone. Rising over the terminal building, the old control tower with its panoramic...
Investing.com
BioMarin The Courier / Apr 29, 2021
Global " Therapeutic Enzymes Market " 2021 Research report produces information with reference to market size, share, trends, growth, cost structure, capacity, revenue, and forecast 2026. This report also contains the general and comprehensive study of the Therapeutic Enzymes Market with all its aspects influencing the growth of the market.
The Courier
BioMarin SoccerNurds / Apr 29, 2021
The Hemophilia A Drug Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
BioMarin SoccerNurds / Apr 29, 2021
The Genetic Disorders Drug Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.
BioMarin Daily Record-News / Apr 28, 2021
SEATTLE and SAN RAFAEL, Calif., April 28, 2021 /PRNewswire/ -- The Allen Institute and BioMarin Pharmaceutical Inc. announced a collaboration today that will use technologies developed at the Allen Institute to create new gene therapies aimed at rare genetic diseases of the central nervous system.
BioMarin Smarter Analyst / Apr 28, 2021
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on BioMarin Pharmaceutical ( BMRN), with a price target of $139.00. The company's shares closed last Wednesday at $80.07, close to its 52-week low of $71.35. According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 12.2% and a 48.2% success rate.
Smarter Analyst
BioMarin Benzinga / Apr 28, 2021
Biomarin Pharmaceutical (NASDAQ: BMRN) releases its next round of earnings this Thursday, April 29. Here is Benzinga's essential guide to Biomarin Pharmaceutical's Q1 earnings report. Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses.
BioMarin Seeking Alpha / Apr 28, 2021
BioMarin Pharmaceutical (NASDAQ:BMRN) is scheduled to announce Q1 earnings results on Thursday, April 29th, after market close.The consensus EPS Estimate is $0.30(-31.8% Y/Y) and...
BioMarin Pharmaceutical Q1 2021 Earnings Preview
Seeking Alpha
BioMarin KSU | The Sentinel Newspaper / Apr 28, 2021
The "Global Hemophilia Market 2025 Key Market Players & Competitive Landscape BioMarin Pharmaceutical and others" report has been added to Zion Market Research 's offering. The Hemophilia Market research report is currently one of the most informative research reports on Hemophilia Market.
KSU | The Sentinel Newspaper
BioMarin Equities.com / Apr 28, 2021
Biomarin Pharmaceuticals (NASDAQ: BMRN) shares gained 0.86% to end trading Wednesday at $80.46 per share - a net change of $0.69. Shares traded between $80.65 and $79.49 throughout the day. 529232 shares of Biomarin Pharmaceuticals exchanged hands. Visit Biomarin Pharmaceuticals's profile for more information.
BioMarin The Courier / Apr 28, 2021
